SEC Form 4 · accession 0001415889-17-000230
MABVAX THERAPEUTICS HOLDINGS, INC. · MBVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul F Resnick
Officer — VICE PRESIDENT, CBO
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001109196
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $2.99 | Feb 6, 2017 | A | 35,000 | A | — | Feb 6, 2027 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1The Option Shares shall vest in three equal annual installments commencing on the first anniversary of the Vesting Commencement Date.